Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (504)	11/3/2005 6:45:11 PM
From: DewDiligence_on_SI	Respond to of 590

>So, IMCL prophet, when you will admit that you are full of BS? You are lost, big time!< I don’t think trying to handicap the results is a form of BS. I figure Pani gets approval fairly easily by hitting the primary PFS endpoint. Many IMCL longs are questioning the fact that the RR results were not disclosed, but I don’t think RR, as a secondary endpoint, will matter given the stellar showing in PFS. An important question for the next couple of years is the degree to which third-party payers (including Medicare) will treat the two drugs as fungible. I’m inclined to think they will not be treated as fungible, and hence Pani’s uptake in combination therapy may be slow until AMGN/ABGX have data using a combo regimen. IMCL clearly has less underlying value today than it had yesterday, but I think the 20% haircut fully accounts for the value shrinkage. I like IMCL at the current price and it could yet be buyout candidate for someone like SGP. Regards, Dew